Vaderis Therapeutics is a clinical-stage biotechnology company developing targeted therapies for rare vascular diseases.
Vaderis Therapeutics has raised $152.0M in total funding. The most recent round was Series B. The last funding was announced in August 2026.
Vaderis Therapeutics's investors include Perceptive Advisors, TCG Crossover, Medicxi, Omega Funds, EQT Life Sciences.
Vaderis Therapeutics is headquartered in Basel, Switzerland.
Vaderis Therapeutics is a clinical-stage biotechnology company developing targeted therapies for rare vascular diseases.
Vaderis Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vaderis Therapeutics — Funding & Investors." VCBacked, August 11, 2026, https://www.vcbacked.co/company/vaderis-therapeutics. Accessed September 3, 2026.
VCBacked. (2026). Vaderis Therapeutics — Funding & Investors. Retrieved September 3, 2026, from https://www.vcbacked.co/company/vaderis-therapeutics
{{cite web |title=Vaderis Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/vaderis-therapeutics |website=VCBacked |access-date=September 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated